[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615700":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":21,"responsibleParty":34,"collaborators":38,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":10,"enrollmentInfo":50,"targetDuration":53,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":10,"overallStatus":59,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Prince of Wales Hospital, Shatin, Hong Kong","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Prospective",null,"Patient planned to undergo a Mitral valve-in-valve\u002Fvalve-in-ring procedure.",{"label":13,"type":10,"description":14,"interventionNames":10},"Retrospective","Patient that had at least one documented Mitral valve-in-valve\u002Fvalve-in-ring procedure done during the period of 1 Jan 2023 to current date.",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Chak Yu Kent So","CONTACT","852-35051518","scy309@ha.org.hk",[22],{"facility":23,"status":10,"city":24,"state":25,"zip":26,"country":24,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":10},"Prince of Wales Hospital","Hong Kong","Shatin","0000","HK",{"type":29,"coordinates":30},"Point",[31,32],114.17469,22.27832,{"lat":32,"lon":31},{"type":35,"investigatorFullName":36,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Dr So Chak Yu kent","Clinical Assistant Professor",[39],{"name":40,"class":6},"National Heart Centre Singapore","100615700","the-asia-pacific-mitral--tricuspid-valve-in-valvevalve-in-ring-registry-100615700",false,"NCT07296016","The Asia-Pacific Mitral & Tricuspid Valve-in-Valve\u002FValve-in-Ring Registry","AP ViV","Inclusion Criteria:\n\n1. Age ≥ 21\n2. Had at least one documented Mitral valve-in-valve\u002Fvalve-in-ring procedure done during the period of 1 Jan 2023 to current date. (Retrospective) OR Planned to undergo a Mitral valve-in-valve\u002Fvalve-in-ring procedure. (Prospective) OR Had at least one documented Tricuspid valve-in-valve\u002Fvalve-in-ring procedure done during the period of 1 Jan 2023 to current date. (Retrospective) OR Planned to undergo a Tricuspid valve-in-valve\u002Fvalve-in-ring procedure. (Prospective)\n\nExclusion Criteria:\n\n1. Active endocarditis\n2. Any other conditions which investigator deems unsuitable for participation.","ALL","21 Years",{"count":51,"type":52},15,"ESTIMATED","10 Years","OBSERVATIONAL","A significant number of patients with severe mitral and tricuspid valve disease have been previously treated with either valve repair with annuloplasty rings or valve replacement with bioprosthetic\u002Fmechanical valves. Over time, these bioprosthetic valves and rings may fail resulting in recurrence of the valvular disease. The technical aspects of a re-do operation are complex and these patients are often times at high risk for repeat open surgery. The emergence of transcatheter options may provide a safer and less invasive alternative to open surgery. Majority of the data currently exist for Western cohorts with limited longer-term outcomes. Data on this therapy is particularly lacking in the Asia-Pacific region, especially important in the light of known differences in body habitus and size.",[57,58],"Structural Heart Disease","Mitral Valve Regurgitation","NOT_YET_RECRUITING","2025-12-16",{"date":62,"type":63},"2025-12-22","ACTUAL",{"date":65,"type":52},"2026-01-05",{"date":67,"type":52},"2035-12-31",{"name":5,"class":6},1]